Pub. Date : 2011 Oct
PMID : 21795446
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | RESULTS: Significantly more patients treated with lorcaserin 10 mg BID and QD lost at least 5% of baseline body weight (47.2 and 40.2%, respectively) as compared with placebo (25.0%, P < 0.001 vs. lorcaserin BID). | lorcaserin | BH3 interacting domain death agonist | Homo sapiens |
| 2 | RESULTS: Significantly more patients treated with lorcaserin 10 mg BID and QD lost at least 5% of baseline body weight (47.2 and 40.2%, respectively) as compared with placebo (25.0%, P < 0.001 vs. lorcaserin BID). | lorcaserin | BH3 interacting domain death agonist | Homo sapiens |
| 3 | Least squares mean (95% confidence interval) weight loss with lorcaserin BID and QD was 5.8% (5.5-6.2%) and 4.7% (4.3-5.2%), respectively, compared with 2.8% (2.5-3.2%) with placebo (P < 0.001 vs. lorcaserin BID; least squares mean difference, 3.0%). | lorcaserin | BH3 interacting domain death agonist | Homo sapiens |
| 4 | Least squares mean (95% confidence interval) weight loss with lorcaserin BID and QD was 5.8% (5.5-6.2%) and 4.7% (4.3-5.2%), respectively, compared with 2.8% (2.5-3.2%) with placebo (P < 0.001 vs. lorcaserin BID; least squares mean difference, 3.0%). | lorcaserin | BH3 interacting domain death agonist | Homo sapiens |
| 5 | Weight loss of at least 10% was achieved by 22.6 and 17.4% of patients receiving lorcaserin 10 mg BID and QD, respectively, and 9.7% of patients in the placebo group (P < 0.001 vs. lorcaserin BID). | lorcaserin | BH3 interacting domain death agonist | Homo sapiens |
| 6 | U.S. Food and Drug Administration-defined echocardiographic valvulopathy occurred in 2.0% of patients on placebo and 2.0% on lorcaserin 10 mg BID. | lorcaserin | BH3 interacting domain death agonist | Homo sapiens |